Yeatman T J, Cantor A B, Smith T J, Smith S K, Reintgen D S, Miller M S, Ku N N, Baekey P A, Cox C E
Department of Surgery, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, USA.
Ann Surg. 1995 Oct;222(4):549-59; discussion 559-61. doi: 10.1097/00000658-199522240-00012.
The purpose of this study was to characterize the biologic determinants that affect the behavior and management of infiltrating lobular cancer.
A prospectively accrued data base containing 1548 breast cancer cases was queried for specific pathologic and mammographic features. From this data base, 777 patients treated and followed-up at the H. Lee Moffitt Cancer Center were reviewed, and comparisons were made between the following three histologic subgroups: 661 infiltrating ductal (ID), 42 infiltrating ductal plus infiltrating lobular (ID + IL), and 74 infiltrating lobular (IL).
Comparisons of the three histologic forms of breast cancer demonstrated the following: 1. At diagnosis tumors with IL components were larger than those with ID components (p < 0.001); in addition, a greater percentage of IL cancers were T3 lesions (14.8%), compared with ID cancers (4.5%). 2. Sizes of IL tumors were underestimated frequently by mammographic examinations when compared with pathologic measurements (p < 0.001). 3. By comparison to ID tumors, increasing IL tumor size is less likely to be associated with an increased number of metastatic lymph nodes per patient (p = 0.09). 4. Infiltrating lobular cancers treated by lumpectomy with cytologic surgical margin analysis more often gave false-negative results than did ID cancers (p < 0.001). 5. Infiltrating lobular cancers treated by lumpectomy required conversion to mastectomy over 2 times more frequently than ID cancers treated by lumpectomy. 6. Mastectomy was performed more frequently than lumpectomy for the treatment of IL versus ID tumors (p = 0.039).
Infiltrating lobular cancers are biologically distinct from ID cancers. Although lumpectomy may be performed safely in selected patients, multiple difficulties exist in the management of IL cancer, particularly when breast conservation is chosen.
本研究旨在明确影响浸润性小叶癌行为及治疗的生物学决定因素。
查询前瞻性积累的包含1548例乳腺癌病例的数据库,以获取特定的病理和乳腺X线特征。从该数据库中,对在H. Lee Moffitt癌症中心接受治疗并随访的777例患者进行回顾,并对以下三个组织学亚组进行比较:661例浸润性导管癌(ID)、42例浸润性导管癌加浸润性小叶癌(ID + IL)和74例浸润性小叶癌(IL)。
对三种组织学类型的乳腺癌进行比较,结果如下:1. 在诊断时,具有IL成分的肿瘤比具有ID成分的肿瘤更大(p < 0.001);此外,与ID癌(4.5%)相比,IL癌中T3病变的比例更高(14.8%)。2. 与病理测量相比,乳腺X线检查经常低估IL肿瘤的大小(p < 0.001)。3. 与ID肿瘤相比,IL肿瘤大小增加时,每位患者发生转移淋巴结数量增加的可能性较小(p = 0.09)。4. 通过肿块切除术加细胞学手术切缘分析治疗的浸润性小叶癌比ID癌更常出现假阴性结果(p < 0.001)。5. 通过肿块切除术治疗的浸润性小叶癌转为乳房切除术的频率比通过肿块切除术治疗的ID癌高出2倍多。6. 与ID肿瘤相比,治疗IL肿瘤时乳房切除术的实施频率更高(p = 0.039)。
浸润性小叶癌在生物学上与ID癌不同。虽然在选定的患者中可以安全地进行肿块切除术,但IL癌的治疗存在多种困难,尤其是在选择保乳治疗时。